Literature DB >> 33716658

The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications.

Miao-Jin Ji1, Jiao Yang1, Zhi-Qiang Gao2, Liang Zhang3, Chao Liu1.   

Abstract

Both pain and psychiatric disorders, such as anxiety and depression, significantly impact quality of life for the sufferer. The two also share a strong pathological link: chronic pain-induced negative affect drives vulnerability to psychiatric disorders, while patients with comorbid psychiatric disorders tend to experience exacerbated pain. However, the mechanisms responsible for the comorbidity of pain and psychiatric disorders remain unclear. It is well established that the kappa opioid system contributes to depressive and dysphoric states. Emerging studies of chronic pain have revealed the role and mechanisms of the kappa opioid system in pain processing and, in particular, in the associated pathological alteration of affection. Here, we discuss the key findings and summarize compounds acting on the kappa opioid system that are potential candidates for therapeutic strategies against comorbid pain and psychiatric disorders.
Copyright © 2021 Ji, Yang, Gao, Zhang and Liu.

Entities:  

Keywords:  KOR agonists; KOR antagonists; cormorbid pain and psychiatric disorders; kappa opioid system; pain-induced negative affect

Year:  2021        PMID: 33716658      PMCID: PMC7943636          DOI: 10.3389/fnins.2021.642493

Source DB:  PubMed          Journal:  Front Neurosci        ISSN: 1662-453X            Impact factor:   4.677


  95 in total

Review 1.  Gating of GIRK channels: details of an intricate, membrane-delimited signaling complex.

Authors:  Rona Sadja; Noga Alagem; Eitan Reuveny
Journal:  Neuron       Date:  2003-07-03       Impact factor: 17.173

2.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Authors:  R Spanagel; A Herz; T S Shippenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Involvement of dopamine system in the regulation of the brain corticotropin-releasing hormone in paraventricular nucleus in a rat model of chronic visceral pain.

Authors:  Ning-Ning Ji; Jie Kang; Rong Hua; Yong-Mei Zhang
Journal:  Neurol Res       Date:  2018-04-06       Impact factor: 2.448

4.  Presynaptic inhibition of gamma-aminobutyric acid release in the bed nucleus of the stria terminalis by kappa opioid receptor signaling.

Authors:  Chia Li; Kristen E Pleil; Alice M Stamatakis; Steven Busan; Linh Vong; Bradford B Lowell; Garret D Stuber; Thomas L Kash
Journal:  Biol Psychiatry       Date:  2012-01-05       Impact factor: 13.382

5.  The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.

Authors:  Kate L White; J Elliott Robinson; Hu Zhu; Jeffrey F DiBerto; Prabhakar R Polepally; Jordan K Zjawiony; David E Nichols; C J Malanga; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-10-15       Impact factor: 4.030

Review 6.  Going with the flow: trafficking-dependent and -independent regulation of serotonin transport.

Authors:  Jennifer A Steiner; Ana Marin D Carneiro; Randy D Blakely
Journal:  Traffic       Date:  2008-04-28       Impact factor: 6.215

7.  Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex.

Authors:  Elyssa B Margolis; Hagar Lock; Vladimir I Chefer; Toni S Shippenberg; Gregory O Hjelmstad; Howard L Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

8.  Kappa Opioid Receptor-Induced Aversion Requires p38 MAPK Activation in VTA Dopamine Neurons.

Authors:  Jonathan M Ehrich; Daniel I Messinger; Cerise R Knakal; Jamie R Kuhar; Selena S Schattauer; Michael R Bruchas; Larry S Zweifel; Brigitte L Kieffer; Paul E M Phillips; Charles Chavkin
Journal:  J Neurosci       Date:  2015-09-16       Impact factor: 6.167

9.  Development of a Peptide-derived orally-active kappa-opioid receptor agonist targeting peripheral pain.

Authors:  Francis M Hughes; Brooke E Shaner; Justin O Brower; R Jeremy Woods; Thomas A Dix
Journal:  Open Med Chem J       Date:  2013-11-04
View more
  4 in total

1.  PET imaging of kappa opioid receptors and receptor expression quantified in neuron-derived extracellular vesicles in socially housed female and male cynomolgus macaques.

Authors:  Bernard N Johnson; Ashish Kumar; Yixin Su; Sangeeta Singh; Kiran Kumar Solingapuram Sai; Susan H Nader; Songye Li; Beth A Reboussin; Yiyun Huang; Gagan Deep; Michael A Nader
Journal:  Neuropsychopharmacology       Date:  2022-09-13       Impact factor: 8.294

Review 2.  An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.

Authors:  Alexander R French; Richard M van Rijn
Journal:  Pharmacol Res       Date:  2022-01-29       Impact factor: 7.658

3.  S-Ketamine Pretreatment Alleviates Anxiety-Like Behaviors and Mechanical Allodynia and Blocks the Pro-inflammatory Response in Striatum and Periaqueductal Gray From a Post-traumatic Stress Disorder Model.

Authors:  Shuai Yang; Ke Xu; Xuan Xu; Jixiang Zhu; Yinan Jin; Qi Liu; Rui Xu; Xiaoping Gu; Yue Liu; Yulin Huang; Zhengliang Ma
Journal:  Front Behav Neurosci       Date:  2022-04-14       Impact factor: 3.617

4.  Asymmetric Syntheses of (+)- and (-)-Collybolide Enable Reevaluation of kappa-Opioid Receptor Agonism.

Authors:  Sophia L Shevick; Stephan M Freeman; Guanghu Tong; Robin J Russo; Laura M Bohn; Ryan A Shenvi
Journal:  ACS Cent Sci       Date:  2022-07-18       Impact factor: 18.728

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.